These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18055311)

  • 1. [Phase I cancer trials methodology].
    Le Tourneau C; Faivre S; Raymond E; Diéras V
    Bull Cancer; 2007 Nov; 94(11):943-51. PubMed ID: 18055311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Accelerated titration design].
    Minami H
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation trial designs based on a molecularly targeted endpoint.
    Hunsberger S; Rubinstein LV; Dancey J; Korn EL
    Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
    Tolcher AW
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):37-43. PubMed ID: 8629035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits associated with novel phase 1 oncology trial designs.
    Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
    Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.